Riluzole to Treat Major Depression

NCT00026052 | Completed Phase 2

• 2 other identifiers: 02003402-M-0034
• Study Type: interventional
• Target: 31
• Locations: 1 country
• Sites: 1

Brief Summary

This study will examine the safety and effectiveness of the drug riluzole (Rilutek® (Registered Trademark)) for short-term treatment of depression symptoms, such as depressed mood, psychomotor retardation, and excessive sleeping. Despite the availability of a wide range of antidepressant drugs, studies indicate that 30 to 40 percent of patients with major depression do not respond to first-line antidepressant treatment with drugs such as fluoxetine, upropion, venlafaxine and others. Riluzole, which is approved by the Food and Drug Administration (FDA) for amyotrophic lateral sclerosis (ALS), causes chemical changes in the brain that may also have antidepressant properties. Patients between 18 and 70 years of age with major depressive disorder without psychotic features may be eligible for this 2-stage 7-week study. Candidates will be screened with a medical history and physical examination, including an electrocardiogram (EKG), blood and urine tests, and a psychiatric evaluation. A blood or urine sample will be tested for illegal drugs.Women of childbearing potential will have a pregnancy test. Participants will complete stage 1 of the study, which lasts 1 week, and may then continue with stage 2 for an additional 6 weeks. At the start of the study, patients will be tapered off all psychiatric medicines and will begin treatment with a placebo (a sugar pill formulated to look like the active drug). At some point, they will be switched from placebo to riluzole. In addition, participants will undergo the following procedures:

• Physical examination and electrocardiograms (EKG) at the beginning and end of the study, with vital signs (temperature, blood pressure and heart rate) checked daily
• Weekly 1-hour interviews consisting of psychiatric and psychomotor rating scales to assess treatment response
• Weekly blood tests to measure blood levels of riluzole and evaluate drug side effects At the end of the study, participants' psychiatric status will be reassessed and appropriate long-term psychiatric treatment arranged. Patients, ages 18 to 70 with a diagnosis of major depression without psychotic features, will in this pilot study (single arm, single blind) receive riluzole (50-200 mg/day) for a period of 6 weeks. Acute efficacy will be determined by demonstrating a greater response rate using specified criteria. Approximately 25 patients will enter the study to obtain 22 subjects who complete the 6 weeks of acute riluzole treatment. Therefore, if 7/22 patients or greater have greater than 50% improvement on the primary efficacy measure, then based on statistically guidelines from the Optimal Two Stage Design for Clinical Trials, a controlled trial would be indicated to scientifically confirm the signal observed in the single arm trial.

Conditions

Depression

Keywords

Riluzole; Neuroprotective; Open-Label Study; Glutamate Dysfunction; Unipolar Depression; Antidepressant; Depression; Major Depression

Interventions

riluzole DRUG

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female subjects, 18 to 70 years of age will be eligible.
• Female subjects of childbearing potential must be using a medically accepted means of contraception.
• Each subject must have a level of understanding sufficient to agree to all required tests and examinations.
• Each subject must understand the nature of the study and must sign an informed consent document.
• Subjects must fulfill the criteria for major depression, recurrent without psychotic features as defined in DSM-IV (296.32, 296.33) based on clinical assessment and confirmed by structured diagnostic interview SCID-P.
• Subjects must have an initial score at Visit 1 and Visit 2 of at least 20 on the MADRS.
• Subjects must not have a decrease in the total score of MADRS of greater than or equal 20% during washout (between Visits 1 and 2).
• Subjects must have experienced, in the opinion of the investigator, at least one prior major depressive episode as defined in DSM-IV (not including the current major depressive episode).
• Subjects must have had at least one adequate antidepressant trial (SSRI, bupropion, or venlafaxine) during an episode of major depression (Thase and Rush, 1995; Thase et al., 2000).
• Subjects with current major depressive episode of no more than 24 months will be eligible.

You may not qualify if:

• Presence of psychotic features.
• Participate in a clinical trial of another investigational drug within 1 month (30 days) prior to study entry (Visit 1).
• Female subjects who are either pregnant or nursing.
• Serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease.
• Subjects with uncorrected hypothyroidism or hyperthyroidism.
• Abnormal levels of serum transaminases (ALT/SGPT; AST/SGOT), current or past blood dyscrasia.
• Documented history of hypersensitivity or intolerance to riluzole.
• DSM-IV substance abuse or dependence within the past 90 days.
• Treatment with an injectable depot neuroleptic within less than one dosing interval between depot neuroleptic injections prior to Visit 2.
• Treatment with a reversible MAOI, guanethidine, or guanadrel within 1 week or with fluoxetine within 3 weeks prior to Visit 2.
• Treatment with any other concomitant medication with primarily CNS activity, other than specified in Appendix A.
• Treatment with clozapine or ECT within 12 weeks prior to Visit 2.
• Current diagnosis of schizophrenia or other psychotic disorder as defined in the DSM-IV will be excluded.
• Judged clinically to be at serious suicidal risk, with a score of 3 or more on item 3 of the HAMD will be excluded.
• Patients will not be allowed to receive structured psychotherapy during the trial.

Sponsors & Collaborators

• National Institute of Mental Health (NIMH): lead

Study Sites (1)

National Institute of Mental Health (NIMH)

Bethesda, Maryland, 20892, United States

Location

Related Publications (3)

• Aronowski J, Strong R, Grotta JC. Combined neuroprotection and reperfusion therapy for stroke. Effect of lubeluzole and diaspirin cross-linked hemoglobin in experimental focal ischemia. Stroke. 1996 Sep;27(9):1571-6; discussion 1576-7. doi: 10.1161/01.str.27.9.1571.

  PMID: 8784132 BACKGROUND

• Altamura CA, Mauri MC, Ferrara A, Moro AR, D'Andrea G, Zamberlan F. Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry. 1993 Nov;150(11):1731-3. doi: 10.1176/ajp.150.11.1731.

  PMID: 8214185 BACKGROUND

• Abe K, Aoki M, Kawagoe J, Yoshida T, Hattori A, Kogure K, Itoyama Y. Ischemic delayed neuronal death. A mitochondrial hypothesis. Stroke. 1995 Aug;26(8):1478-89. doi: 10.1161/01.str.26.8.1478.

  PMID: 7631357 BACKGROUND

MeSH Terms

Conditions

Depression; Depressive Disorder; Depressive Disorder, Major

Interventions

Riluzole

Condition Hierarchy (Ancestors)

Behavioral Symptoms; Behavior; Mood Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Thiazoles; Sulfur Compounds; Organic Chemicals; Benzothiazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Study Design

• Study Type: interventional
• Phase: phase 2
• Purpose: TREATMENT
• Sponsor Type: NIH

Study Record Dates

• First Submitted: November 8, 2001
• First Posted: November 9, 2001
• Study Start: November 1, 2001
• Study Completion: April 1, 2003
• Last Updated: March 4, 2008

Record last verified: 2003-04

Locations

US (1)